About Alcresta Therapeutics

Alcresta Therapeutics, the makers of RELiZORB, is dedicated to developing and commercializing novel enzyme-based products designed to address challenges faced by people living with serious diseases, such as cystic fibrosis and digestive cancers.

The company uses its proprietary technology platform to support a pipeline of products, with an initial focus on fat malabsorption addressed by RELiZORB, a first-of-its-kind digestive enzyme cartridge.

Based in Massachusetts, Alcresta Therapeutics has made significant scientific and development advances in its product pipeline and is developing a portfolio of point-of-care enzyme-based products designed to address the need for improved nutritional care in a number of medical conditions.

Learn more about Alcresta Therapeutics at the company’s website